Esquire Financial Holdings And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) – Esquire Financial Holdings (ESQ), Halozyme Therapeutics (HALO), Annaly Capital (NLY) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Esquire Financial Holdings (ESQ)

40.4% sales growth and 18.89% return on equity

Esquire Financial Holdings, Inc. operates as the bank holding company for Esquire Bank, National Association that provides commercial banking products and services to legal industry and small businesses, and commercial and retail customers in the United States. The company offers checking, savings, money market, and time deposits, as well as certificates of deposit. It also provides commercial loans, including short-term financing for inventory, receivables, the purchase of supplies, or other operating needs arising during the normal course of business, as well as loans to its qualified merchant customers; commercial lines of credit; consumer loans consisting of post-settlement consumer and structured settlement loans to plaintiffs and claimants, as well as loans to individuals for debt consolidation, medical expenses, living expenses, payment of outstanding bills, or other consumer needs; and real estate loans, such as multifamily, 1-4 family residential, commercial real estate, and construction loans, as well as merchant services. As of December 31, 2020, the company operated a full-service branch in Jericho, New York; and an administrative office in Boca Raton, Florida. Esquire Financial Holdings, Inc. was founded in 2006 and is headquartered in Jericho, New York.

Earnings Per Share

As for profitability, Esquire Financial Holdings has a trailing twelve months EPS of $3.4.

PE Ratio

Esquire Financial Holdings has a trailing twelve months price to earnings ratio of 13.25. Meaning, the purchaser of the share is investing $13.25 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.89%.

2. Halozyme Therapeutics (HALO)

31% sales growth and 110.23% return on equity

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Earnings Per Share

As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $1.35.

PE Ratio

Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 26.72. Meaning, the purchaser of the share is investing $26.72 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 110.23%.

Volume

Today’s last reported volume for Halozyme Therapeutics is 5389050 which is 341.95% above its average volume of 1219370.

Revenue Growth

Year-on-year quarterly revenue growth grew by 77.9%, now sitting on 660.12M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Halozyme Therapeutics’s EBITDA is 10.63.

3. Annaly Capital (NLY)

29% sales growth and 14.06% return on equity

Annaly Capital Management, Inc., a diversified capital manager, engages in mortgage finance and corporate middle market lending. The company invests in agency mortgage-backed securities, mortgage servicing rights, Agency commercial mortgage-backed securities, non-Agency residential mortgage assets, residential mortgage loans, credit risk transfer securities, corporate debts, and other commercial real estate investments. It has elected to be taxed as a real estate investment trust (REIT). As a REIT, it is not subject to federal income tax to the extent that it distributes its taxable income to its shareholders. The company was founded in 1996 and is based in New York, New York.

Earnings Per Share

As for profitability, Annaly Capital has a trailing twelve months EPS of $3.1.

PE Ratio

Annaly Capital has a trailing twelve months price to earnings ratio of 6. Meaning, the purchaser of the share is investing $6 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.06%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 24.1% and a negative 28.3%, respectively.

4. Summit Financial Group (SMMF)

20.1% sales growth and 15.61% return on equity

Summit Financial Group, Inc. operates as a financial holding company for Summit Community Bank, Inc. that provides community banking and other financial services to individuals and businesses primarily in the Eastern Panhandle, Southern and North Central regions of West Virginia and the Northern, and Shenandoah Valley and Southwestern regions of Virginia, and the Central region of Kentucky. The company's community banking services include demand, savings, and time deposits; commercial, commercial real estate, construction and land development, residential real estate, and consumer loans; and mortgage warehouse lines of credit, as well as trust and wealth management, cash management, and insurance brokerage services. As of December 31, 2020, it operated through 43 banking offices. The company was incorporated in 1987 and is headquartered in Moorefield, West Virginia.

Earnings Per Share

As for profitability, Summit Financial Group has a trailing twelve months EPS of $4.22.

PE Ratio

Summit Financial Group has a trailing twelve months price to earnings ratio of 5.2. Meaning, the purchaser of the share is investing $5.2 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.61%.

Sales Growth

Summit Financial Group’s sales growth is 16.6% for the ongoing quarter and 20.1% for the next.

Yearly Top and Bottom Value

Summit Financial Group’s stock is valued at $21.96 at 20:22 EST, way under its 52-week high of $30.83 and higher than its 52-week low of $20.89.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Mar 13, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 3.77%.

5. Ingredion Incorporated (INGR)

13.7% sales growth and 15.68% return on equity

Ingredion Incorporated, together with its subsidiaries, produces and sells starches and sweeteners for various industries. It operates through four segments: North America; South America; Asia Pacific; and Europe, Middle East, and Africa. The company offers sweetener products comprising glucose syrups, high maltose syrups, high fructose corn syrups, caramel colors, dextrose, polyols, maltodextrins, glucose and syrup solids, as well as food-grade and industrial starches, biomaterials, and nutrition ingredients. It also provides animal feed products; edible corn oil; refined corn oil to packers of cooking oil and to producers of margarine, salad dressings, shortening, mayonnaise, and other foods; and corn gluten feed used as protein feed for chickens, pet food, and aquaculture. The company's products are derived primarily from processing corn and other starch-based materials, such as tapioca, potato, and rice. It serves food, beverage, paper and corrugating products, brewing, pharmaceutical, textile, and personal care industries, as well as animal feed markets. The company was formerly known as Corn Products International, Inc. and changed its name to Ingredion Incorporated in June 2012. Ingredion Incorporated was founded in 1906 and is headquartered in Westchester, Illinois.

Earnings Per Share

As for profitability, Ingredion Incorporated has a trailing twelve months EPS of $7.22.

PE Ratio

Ingredion Incorporated has a trailing twelve months price to earnings ratio of 13.28. Meaning, the purchaser of the share is investing $13.28 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.68%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Ingredion Incorporated’s EBITDA is 1.13.

Moving Average

Ingredion Incorporated’s value is below its 50-day moving average of $99.98 and above its 200-day moving average of $92.38.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Dec 28, 2022, the estimated forward annual dividend rate is 2.84 and the estimated forward annual dividend yield is 2.91%.

Leave a Reply

Your email address will not be published. Required fields are marked *